Zepp Health (ZEPP) Files Form 144 to Sell 1,745 ADRs
Rhea-AI Filing Summary
Zepp Health Corporation (ZEPP) filing a Form 144 notifies a proposed sale of 1,745 ADRs representing American depositary shares, with an aggregate market value of $60,656.20. The ADRs trade on the NYSE and the filing lists an approximate sale date of 08/27/2025. The securities were acquired through the vesting of restricted share units from Zepp Health between March 2018 and February 2020, and no sales by the holder in the past three months were reported.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine Form 144 disclosure of a small proposed ADR sale stemming from vested RSUs; mainly a compliance notice.
The filing documents a proposed sale of 1,745 ADRs with an aggregate market value of $60,656.20 on NYSE, scheduled approximately 08/27/2025. All reported acquisitions are described as vesting of restricted share units between 2018 and 2020. No securities sales in the past three months are listed. From a compliance perspective, this aligns with Rule 144 notice requirements and signals the holder is notifying the market of intent to sell vested shares rather than a corporate event.
TL;DR: Small-scale insider/affiliate sale notice; unlikely to be market-impactful given size relative to outstanding shares.
The proposed sale quantity (1,745 ADRs) represents a negligible fraction of the reported 7,040,000 ADRs outstanding, implying limited potential impact on supply or market price. The acquisitions were all via RSU vesting, indicating these are previously earned compensatory awards rather than new issuances. The absence of recent sales by the holder and the routine nature of the disclosure suggest this is a standard liquidity event by an insider or former insider.